Table 1.
The Basic Characteristic of Enrolled Studies.
| Study | Period | Country | Histology | Sample size | MFP | Age(Median) | M/F |
|---|---|---|---|---|---|---|---|
| Huang, Q 2020 | 2012-2014 | China | NSCLC | 254 | 48 | 60.2 ± 9.5# | 186/68 |
| Katayama, Y 2020 | 2017-2018 | Japan | NSCLC | 35 | NM | 70 | 24/11 |
| Takada, K 2020 | 2016-2018 | Japan | NSCLC | 226 | 413(days) | 66 | 184/42 |
| Xue,Yuan 2020 | 2009-2011 | China | NSCLC | 538 | 54 | 60 | 343/195 |
| Guo M 2019 | 2015-2016 | China | NSCLC | 370 | NM | NM | 312/58 |
| Prelaj A 2019 | 2015-2018 | Italy | NSCLC | 154 | NM | 67 | 126/28 |
| Yan,Wang 2019 | 2014-2016 | China | NSCLC | 261 | 38 | NM | 144/117 |
| Zhang Y 2018 | 2013-2015 | China | NSCLC | 127 | 28 | 61.9¶ | 55/72 |
| Watanabe K 2018 | 2008-2017 | Japan | NSCLC | 72 | 26 | 69 | 31/41 |
| Minami S 2018 | 2007-2017 | Japan | NSCLC | 107 | NM | 70.2 ± 8.2# | 82/25 |
| Minami Seigo 2018 | 2007-2017 | Japan | NSCLC | 159 | NM | 67.2 ± 9.0# | 114/45 |
| Luo H 2018 | 2011-2015 | China | NSCLC | 63 | 30 | 73 | 49/14 |
| Lim JU 2018 | 2012-2016 | Korea | NSCLC | 217 | NM | 68 | 120 97 |
| Chen Y 2018 | 1999-2009 | China | NSCLC | 577 | 94 | 60 | 410/167 |
| Xiong Y 2017 | 2012-2015 | China | NSCLC | 78 | NM | 59 | 36/42 |
| Liu W 2017 | 2007-2011 | China | NSCLC | 1120 | 45 | 60 | 728/392 |
| Gao Y 2017 | 2007-2008 | China | NSCLC | 358 | 36 | 61 | 247/111 |
| Cao S 2017 | 2008-2010 | China | SCLC | 707 | NM | 56.24 ± 10.15# | 454/253 |
| Xia H 2016 | 2005-2010 | China | NSCLC | 439 | 57 | 62 | 287/152 |
| Song Ying-Jian 2016 | 2006-2010 | China | NSCLC | 488 | 48 | 64 | 359/129 |
| Lin Gui-Nan 2014 | 2004-2012 | China | NSCLC | 370 | NM | 64 | 213/157 |
| Pingping Hu 2014 | 2006-2011 | China | NSCLC/SCLC | 1453 | NM | 59 | 1035/418 |
| Go Se-II 2014 | 2006-2014 | Korea | SCLC | 188 | 42 | NM | 163/25 |
| Study | SCC% | Treatment | Outcome | Stage | NOS | Smoker% | Cut-off |
| Huang, Q 2020 | 44 | Chemotherapy+ Radiotherapy | OS/DFS | I-IV | 7 | 59 | 4.04 |
| Katayama, Y 2020 | 29 | Immunotherapy | OS/PFS/RR/DCR | III/IV/REC | 6 | 77 | 1.70 |
| Takada, K 2020 | 27 | Immunotherapy | OS/PFS/RR/DCR | IIIB/IV/REC | 6 | 84 | 2.12 |
| Xue,Yuan 2020 | 47 | Surgery | OS/DFS | I/II/IIIA | 7 | 64 | 3.17 |
| Guo M 2019 | 63 | Chemotherapy | OS/PFS | III | 7 | NM | 2.38 |
| Prelaj A 2019 | 42 | Immunotherapy | OS/PFS/RR/DCR | IIIB/IV | 7 | 83 | 1.80 |
| Yan,Wang 2019 | 18 | Surgery | OS/DFS | I/II/III | 6 | 47 | 4.57 |
| Zhang Y 2018 | 8 | TKI | OS/PFS | IIIB/IV | 6 | 28 | 3.37 |
| Watanabe K 2018 | NM | TKI | OS/PFS | IIIA/IIIB/IV/REC | 6 | 47 | 2.80 |
| Minami S 2018 | 100 | Chemotherapy | OS/PFS/RR | IIIB/IV/REC | 8 | NM | 2.07 |
| Minami Seigo 2018 | 0 | Chemotherapy | OS/PFS/RR | IIIB/IV | 8 | NM | 1.97 |
| Luo H 2018 | 40 | SABR | OS | I/IIA | 7 | 67 | 4.00 |
| Lim JU 2018 | 14 | Chemotherapy+TKI | OS/PFS | IV | 7 | 45 | 2.47 |
| Chen Y 2018 | 33 | Surgery | OS | IB | 8 | 59 | 3.16 |
| Xiong Y 2017 | 0 | Chemotherapy | OS/PFS | IIIB/IV | 7 | 53 | 4.30 |
| Liu W 2017 | 47 | Surgery | OS/DFS | I/II/IIIA | 6 | 66 | 3.60 |
| Gao Y 2017 | 45 | Surgery | OS | I/II/III | 7 | 68 | 3.06 |
| Cao S 2017 | 0 | Chemotherapy+ Radiotherapy | OS | LD/ED | 6 | 63 | 2.62 |
| Xia H 2016 | 41 | Surgery | OS/RFS | I | 6 | 42 | 4.00 |
| Song Ying-Jian 2016 | NM | Chemotherapy | OS/PFS | I/II | 7 | 90 | 4.50 |
| Lin Gui-Nan 2014 | 53 | Chemotherapy | OS/PFS | IIIB/IV | 6 | NM | 4.56 |
| Pingping Hu 2014 | NM | Surgery | OS/DFS | I/II/III | 8 | 54 | 3.68 |
| Go Se-II 2014 | 0 | Chemotherapy+ Radiotherapy | OS/PFS | LD/ED | 6 | 91 | 4.19 |
Abbreviation: NM: not mentioned; M/F: male/female; MFP: Median follow-up (month); SCC%: Proportion of Squamous cell carcinoma; OS: overall survival; PFS: progress free survival; RFS: recurrence-free survival; DFS: disease free survival; DCR: disease control rate; RR: response rate; REC: recurrent NSCLC who were treated with anti-PD-1 therapy; TKI: Tyrosine kinase inhibitors; SABR: Stereotactic Ablative Radiotherapy; ED: Extensive-stage; LD: Limited-stage; NOS: Ottawa quality assessment Scale; ¶: the study just provided the mean value of age; #:the study provided the mean and standard error value of age.